Results 31 to 40 of about 6,491 (191)

Effectiveness of palivizumab immunoprophylaxis in infants with respiratory syncytial virus disease in Colombia

Journal of Infection in Developing Countries, 2021
Introduction: Respiratory syncytial virus (RSV) is one of the most important childhood infections. Objective: To evaluate the effectiveness and safety of palivizumab immunoprophylaxis in preterm infants at a high risk of severe respiratory syncytial ...
Juan Gabriel Piñeros, Jose De la Hoz-Valle, Clara Galvis, Astrid Celis, Oscar Ovalle, Carmen Cecilia Sandoval, Jaime Orrego, Saby Vides, Iader Rojas, Hernando Bustamante, Carlos Gallón, Jaime Alberto Mesa   +11 more
doaj   +1 more source

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

Italian Journal of Pediatrics, 2009
Introduction The aim of this study was to assess the cost-utility of palivizumab versus no prophylaxis in the prevention of respiratory syncytial virus infection among high-risk preterm infants.
Ravasio Roberto, Chirico Gaetano, Sbarigia Urbano   +2 more
doaj   +1 more source

Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection

Scientific Reports, 2021
Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations.
Agata Antepowicz, Omar Habib, Freja Kirsebom, Cecilia Johansson, Deborah R. Gill, Stephen C. Hyde   +5 more
doaj   +1 more source

The influence of respiratory syncytial virus immunoprophylaxis on allergic sensitisation in children with respiratory allergy

Journal of Microbiology, Immunology and Infection
Background: Respiratory syncytial virus (RSV) infection may induce asthma and allergic sensitisation. RSV immunoprophylaxis can reduce the severity of RSV infections. However, the effects of RSV immunoprophylaxis on allergic sensitisation remains unclear.
Li-Ching Fang, Jen-Yu Wang
doaj   +1 more source

The New Era of Respiratory Syncytial Virus Protection for Infants: A Mini Review of Current Tools for Immunoprophylaxis

Acta Paediatrica, EarlyView.
ABSTRACT Aim This mini review describes the history of infant respiratory syncytial virus (RSV) immunoprophylaxis and the latest advances in this area. It also reviews the efficacy, safety and impact of the recently introduced prophylactic strategies. Method This narrative review is based on a targeted review of published literature, with emphasis on ...
Santtu Heinonen, Pekka Vartiainen
wiley   +1 more source

Frequency, Burden and Pathogens of Acute Respiratory Illness in Very Preterm Infants During Infancy

Acta Paediatrica, EarlyView.
ABSTRACT Aim To describe the frequency, burden, and pathogen profile of acute respiratory illnesses (ARIs) in very preterm infants during the first year after neonatal intensive care unit (NICU) discharge. Methods Very preterm infants were followed prospectively (August 2015–January 2017) with monthly assessments of symptoms, medication use, and ...
Patricia De Gouveia Belinelo, Nada Townsi, Naomi R. Hemy, Chisha T. Sikazwe, David W. Smith, Benjamin Stoecklin, J. Jane Pillow, Graham L. Hall, Ingrid A. Laing, Shannon J. Simpson   +9 more
wiley   +1 more source

Intermediate‐Phenotype ABCA3 Deficiency Caused by Compound Heterozygous Variants Presenting as Persistent Respiratory Failure and Systemic Hypertension Since Birth in a Term Infant: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT ABCA3 deficiency should be suspected in term infants with persistent respiratory distress from birth. This case highlights how early whole‐exome sequencing established the diagnosis after extensive investigations, identified an intermediate phenotype caused by compound heterozygous variants, and guided targeted multidisciplinary management.
Ammir Abuzahra, Mohamad Abu Mayalah, Mahmoud Abdelrazzaq Abu Mayaleh, Amani Daabes, Rafad Y. Dweik, Abdelrazzaq Abu Mayaleh   +5 more
wiley   +1 more source

Passive immunisation of preterm infants with palivizumab against RSV infection

Palivizumab is a monocloncal antibody used for prevention of respiratory syncytial virus infection. This study reviews the literature regarding evidence of efficacy, safety and cost-effectiveness.
Harkensee C, Brodlie M, Embleton ND, Mckean M   +3 more
core   +5 more sources

Palivizumab coverage rates among moderate-to-late preterm infants in Korea: a nationwide cross-sectional study [PDF]

Epidemiology and Health
OBJECTIVES Since October 2016, Korea has implemented a national reimbursement program for palivizumab aimed at moderate-to-late preterm (MLPT) infants born between 32 0/7 weels and 35 6/7 weeks of gestation during the respiratory syncytial virus (RSV ...
Seungyeon Kim, Saram Lee, Young June Choe, Ju Sun Heo   +3 more
doaj   +1 more source

Qianjinweijingtang Decoction and Its Granule Inhibit Respiratory Syncytial Virus Infection and the Associated Inflammatory Response

Chemistry &Biodiversity, Volume 23, Issue 9, September 2026.
The classical herbal formula Qianjinweijingtang in both decoction and granule forms, exhibits anti‐RSV activity. Isoliquiritigenin, quercetin, and gallic acid are identified as key active compounds. The mechanism involves interfering with viral entry and downregulating HIF‐1α and inflammatory responses, positioning the granule formulation as a ...
Chu‐Yi Liao, Mei‐Lan Yang, Ze‐Ping Chen, Bin Chen, Yu‐Jun Tang, Zhen Wang, Hui‐Nan Zhao, Su‐Hua Deng, Jin‐Hai Ye, Zhong Liu, Li‐Feng Chen, Man‐Mei Li   +11 more
wiley   +1 more source